Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9249543rdf:typepubmed:Citationlld:pubmed
pubmed-article:9249543lifeskim:mentionsumls-concept:C0027882lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C0033093lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C1705480lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C1417869lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:9249543lifeskim:mentionsumls-concept:C1708517lld:lifeskim
pubmed-article:9249543pubmed:issue1 Pt 2lld:pubmed
pubmed-article:9249543pubmed:dateCreated1997-9-3lld:pubmed
pubmed-article:9249543pubmed:abstractTextArginine vasopressin (AVP) may act as a neurotransmitter or neuromodulator in the solitary tract nucleus (NTS). To determine whether AVP influences the activity of NTS neurons receiving cardiovascular afferent input, we used single-unit extracellular recording combined with local microinjection to test the effects of AVP and V1-receptor antagonists (antAVP) on spontaneously active NTS neurons in anesthetized rats. Phenylephrine-induced increases in arterial pressure were used to identify neurons receiving baroreceptor input. Phenylbiguanide was used to stimulate chemosensitive cardiopulmonary receptors. AVP excited 31 of 81 NTS neurons tested and inhibited 15 of 81 neurons. AntAVP had independent effects on NTS neurons: in addition to blocking the effects of AVP, antAVP inhibited 26 of 72 neurons but excited only 13. Eighty-two percent of NTS neurons receiving excitatory or inhibitory baroreceptor inputs responded to AVP; 61% of these were excited by AVP. Fifty-eight percent of neurons receiving cardiopulmonary receptor input responded to AVP. These results suggest that AVP in rat NTS has a tonic, predominantly excitatory influence on a significant proportion of baroreceptor-related neurons.lld:pubmed
pubmed-article:9249543pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:languageenglld:pubmed
pubmed-article:9249543pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:citationSubsetIMlld:pubmed
pubmed-article:9249543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9249543pubmed:statusMEDLINElld:pubmed
pubmed-article:9249543pubmed:monthJullld:pubmed
pubmed-article:9249543pubmed:issn0002-9513lld:pubmed
pubmed-article:9249543pubmed:authorpubmed-author:FelderR BRBlld:pubmed
pubmed-article:9249543pubmed:authorpubmed-author:HegartyA AAAlld:pubmed
pubmed-article:9249543pubmed:issnTypePrintlld:pubmed
pubmed-article:9249543pubmed:volume273lld:pubmed
pubmed-article:9249543pubmed:ownerNLMlld:pubmed
pubmed-article:9249543pubmed:authorsCompleteYlld:pubmed
pubmed-article:9249543pubmed:paginationR143-52lld:pubmed
pubmed-article:9249543pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:meshHeadingpubmed-meshheading:9249543-...lld:pubmed
pubmed-article:9249543pubmed:year1997lld:pubmed
pubmed-article:9249543pubmed:articleTitleVasopressin and V1-receptor antagonists modulate the activity of NTS neurons receiving baroreceptor input.lld:pubmed
pubmed-article:9249543pubmed:affiliationCardiovascular Center, University of Iowa College of Medicine, Iowa City 52242, USA. ahegarty@blue.weeg.uiowa.edulld:pubmed
pubmed-article:9249543pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9249543pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9249543pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9249543lld:pubmed